Comprehensive Analysis of Aberrantly Expressed Competitive Endogenous RNA Network and Identification of Prognostic Biomarkers in Pheochromocytoma and Paraganglioma

This article was published in the following Dove Press journal:
OncoTargets and Therapy

Zijun Wang¹
Yijian Li²
YanJun Zhong³
Yinhuai Wang²
Mou Peng^{2,4}

¹Department of Dermatology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, People's Republic of China; ²Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, People's Republic of China; ³ICU Center, The Second Xiangya Hospital, Central South University, Hunan, Hunan 410011, People's Republic of China; ⁴Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA

Background: Long non-coding RNA (lncRNA) functions as a competitive endogenous RNA (ceRNA) and plays an important role in the biological processes underlying tumorigenesis. However, studies describing the function of lncRNA in pheochromocytoma and paraganglioma (PCPG) remain largely unknown. Our study aims to construct a regulatory ceRNA network and explore prognostic biomarkers for PCPG through a comprehensive analysis.

Methods: PCPG data from The Cancer Genome Atlas (TCGA) were utilized to obtain differentially expressed lncRNAs (DELncRNAs), microRNAs (DEmiRNAs), and mRNAs (DEmRNAs). Kaplan–Meier analysis was used to detect prognostic biomarkers and Cytoscape was utilized to construct a regulatory network of ceRNA. Potential lncRNA–miRNA–mRNA axes were inferred by correlation analysis. GO and KEGG pathways were constructed using “clusterProfiler” and “DOSE” R-packages. Immunohistochemistry (IHC) staining was performed to validate differential protein expression levels of genes in the axes. Finally, the GSE19422 dataset and Pan-Cancer data were applied to validate the expression pattern and survival status of mRNAs, respectively.

Results: A total of 334 DELncRNAs, 116 DEmiRNAs, and 3496 DEmRNAs were identified and mainly enriched in hormone secretion, metabolism signaling, metastatic and proliferative pathways. Among these differentially expressed genes, 16 mRNAs, six lncRNAs, and two miRNAs were associated with overall survival of patients with PCPG and sequentially enrolled in the ceRNA network. Two lncRNA–miRNA–mRNA regulatory axes were predicted: *AP001486.2/hsa-miR-195-5p/RCAN3* and *AP006333.2/hsa-miR-34a-5p/PTPRJ*. The GSE19422 dataset and IHC analysis validated that mRNA and protein levels of *RCAN3* and *PTPRJ* were upregulated in PCPG tissues compared with adjacent adrenal gland medulla tissues. Pan-Cancer data showed that the upregulated expression of *RCAN3* and *PTPRJ* was associated with favorable overall survival and disease-free survival.

Conclusion: A regulatory lncRNA–miRNA–mRNA ceRNA network was successfully constructed and 24 prognostic biomarkers were identified for PCPG patients. These findings may contribute toward a better understanding of the biological mechanism of tumorigenesis and enable further evaluation of the prognosis of patients with PCPG.

Keywords: pheochromocytoma and paraganglioma (PCPG), prognostic biomarker, ceRNA network

Correspondence: Mou Peng
Department of Urology, The Second Xiangya Hospital, Central South University, No. 139 Renmin Middle Road, Changsha, Hunan 410011, People's Republic of China
Tel/Fax +86-731-85295134
Email pengmou@csu.edu.cn

Introduction

Pheochromocytoma and paraganglioma (PCPG) is a neuroendocrine tumor originating from chromaffin cells and sympathetic chains, characterized by the

production of catecholamines.¹ Previous studies have shown that mutations in susceptibility genes of PCPG provide a basis for explaining the occurrence and development of PCPG.² Patients with PCPG are typically characterized by severe hypertension, irritability, sweating, and other symptoms, potentially leading to serious complications such as cerebral hemorrhage and heart disease. At present, the diagnosis of PCPG mainly depends on medical history, physical examination, biochemical tests, and imaging examinations. Nevertheless, it is difficult to diagnose and perform effective preoperative preparation in the absence of catecholamine secretion. In addition, malignant PCPG can only be diagnosed when a metastasis is found, resulting in a poor prognosis. Novel molecular markers are helpful to clearly distinguish between benign and malignant PCPG.^{3,4} In order to confirm the diagnosis and characterization of PCPG, it is therefore necessary to explore the mechanisms of tumorigenesis and metastasis in PCPG.

Long non-coding RNA (lncRNA) is a non-coding RNA greater than 200 nucleotides in length. In recent years, studies have found that lncRNA is involved in many biological processes and plays an important role in tumorigenesis, progression, and metastasis.⁵ A few studies have examined lncRNA in PCPG.^{6,7} However, the specific role of other lncRNAs in PCPG is unclear. With the introduction of the competitive endogenous RNA (ceRNA) hypothesis and the understanding of the lncRNA–miRNA–mRNA network regulation mechanism, it has been shown that lncRNA directly silences mRNA expression and indirectly acts as a “sponge” of microRNA (miRNA) to regulate mRNA. As a post-transcriptional product, lncRNA performs as an miRNA sponge to fully bind to miRNA, reducing the binding of miRNA to mRNA, which results in decreased mRNA silencing and increased mRNA expression.⁸ Through the study of ceRNA regulatory networks, we can further understand the role of lncRNA in PCPG and identify prognostic biomarkers for PCPG.

In this study, we collected differentially expressed lncRNA (DELncRNA), differentially expressed miRNA (DEmiRNA), and differentially expressed mRNA (DEmRNA) in PCPG tissues compared with adjacent adrenal gland medulla tissues, based on The Cancer Genome Atlas (TCGA) database. We found differentially expressed mRNAs involved in hormone secretion, metabolism signaling pathways, and tumorigenesis biological behaviors. Through integration analysis, we constructed an lncRNA–miRNA–mRNA network for ceRNA analysis in PCPG. Subsequently, we obtained two lncRNA–miRNA–mRNA

axes in PCPG and performed Kaplan–Meier survival analysis to identify prognostic biomarkers. We further validated the mRNA and protein expression of prognostic biomarkers by the Gene Expression Omnibus (GEO) database and immunohistochemistry (IHC) staining, separately.

Methods

RNA-Seq, miRNA Data, and Clinical Data from TCGA-PCPG

R-packaged GDCRNATools were utilized in this study.⁹ RNA sequencing (RNA-seq), miRNA, and clinical features of TCGA-PCPG data were downloaded from TCGA (<https://portal.gdc.cancer.gov/>). The RNA-seq and miRNA data from different patients were integrated separately into two files. Duplicated samples were removed from the RNA-seq matrix and miRNA matrix and the count data of duplicated genes were averaged. Raw count data were normalized by the trimmed mean of M values (TMM) method implemented in edgeR and further transformed by the voom method provided in limma. Low-expression genes (logCPM <1 in more than half of the samples) were filtered out. Differentially expressed genes were subsequently calculated by the “edgeR” package by comparing PCPG with normal adrenal gland tissue.

Identification of Differentially Expressed lncRNA, miRNA, and mRNA

All long non-coding genes and protein coding genes were separately reported by setting the “gene Type” argument in “gdcDEReport”. Gene symbols and biotypes based on the Ensembl 38.90 annotation were reported in the output. DELncRNA and DEMRNA were identified by inclusion criteria. The inclusion criteria were “|log2(fold change)| >2, FDR <0.05”. The same procedure was performed with miRNA data to find DEMiRNA. Volcano maps and heatmaps of lncRNA, miRNA, and mRNA were then constructed.

GO and KEGG Pathway Analysis

A functional enrichment analysis of differentially expressed mRNAs was performed via the R/Bioconductor packages “clusterProfiler” and “DOSE”. Gene Ontology (GO) and the Kyoto Gene and Genomic Encyclopedia (KEGG) were analyzed and the bubble maps of the GO and KEGG pathways were drawn. After generating the ceRNA network, mRNAs in the ceRNA network were analyzed for GO and KEGG enrichment analysis via R packages.

Figure 1 Workflow of the study.

Abbreviations: TCGA, The Cancer Genome Atlas; PCPG, pheochromocytoma and paraganglioma; FC, fold change; FDR, false discovery rate; lncRNA, long non-coding RNA; miRNA, microRNA; mRNA, messenger RNA; ceRNA, competitive endogenous RNA; GO, gene ontology; KEGG, Kyoto Gene and Genomic Encyclopedia.

Survival Analysis

Survival analysis of differentially expressed lncRNA, miRNA, and mRNA in PCPG was performed with GDCRNATools. RNAs with p -value <0.05 were identified as prognostic biomarkers.

Expression Level of Prognostic Biomarkers Between Metastatic and Non-Metastatic PCPG Groups

Based on the clinical file downloaded by the GDCRNATools package, 168 PCPG patients with metastatic status were enrolled in this study and the clinical data and normalized expression value of prognostic markers were extracted. The unpaired t -test was used for statistical analysis. GraphPad version 8.3.1 was used to display the results.

Construction of lncRNA–miRNA–mRNA ceRNA Regulatory Network

Based on RNA-seq and miRNA data, lncRNA–miRNA interactions and mRNA–miRNA interactions were analyzed to search for shared miRNAs. There are three criteria for determining the ceRNA between lncRNA and mRNA. First, lncRNA and mRNA share a certain number of miRNAs. Second, the correlation between lncRNA and mRNA expression is positive. Third, those shared miRNAs should have similar effects to regulate the expression levels of lncRNA and mRNA.⁹ The miRcode database was used to predict lncRNA–miRNA interactions, and mirTarBase database was used to predict mRNA–miRNA interactions. The correlation coefficient was measured to assess the linear association between lncRNA and mRNA. Modulation of similarity and sensitivity correlations was used to calculate the possible regulatory effects of consensus miRNAs on lncRNA and

Figure 2 Differentially expressed miRNAs, mRNAs, and lncRNAs in tumor and normal adrenal gland tissues. **(A)** Volcano plots of miRNAs, mRNAs, and lncRNAs. Red: upregulated in tumor tissues. Green: upregulated in normal adrenal gland tissues. **(B)** Heatmap of differentially expressed lncRNAs (334 lncRNAs), differentially expressed mRNAs (3496 genes), and differentially expressed miRNAs (116 miRNAs).

Abbreviations: miRNA, microRNA; lncRNA, long non-coding RNA; PCPG, pheochromocytoma and paraganglioma; FDR, false discovery rate.

mRNA. hyperPValue <0.01 and corPValue <0.01 were set for analysis. Prognostic lncRNA, differentially expressed miRNA, and prognostic mRNA were selected to generate the “node” and “edge” files. Then, we imported the node and edge data into Cytoscape to build a ceRNA network.

Prediction of lncRNA–miRNA–mRNA Axis and Correlations Between PCPG Genotypes and the lncRNA–miRNA–mRNA Axis

It is well known that shared miRNAs are capable of binding lncRNAs and mRNAs. The more miRNAs bind to the lncRNAs, the fewer miRNAs will bind to the mRNAs. High mRNA expression is associated with more lncRNAs and fewer miRNAs. According to this trend, the lncRNA–miRNA–mRNA axis was identified from the ceRNA network. The correlations between lncRNAs and mRNAs were further calculated to confirm the regulatory axis.

Based on 17 susceptibility genes, patients with PCPG were divided into four genotypes: the pseudohypoxia group,

the kinase signaling group, the Wnt signaling group, and the disease-modifying gene group.¹⁰ The expression of susceptibility genes and lncRNA–miRNA–mRNA axis genes in PCPG was extracted and Pearson correlation analysis was used to analyze the correlations between PCPG genotypes and lncRNA–miRNA–mRNA axis.

Validation of mRNA Expression and Survival in Pan-Cancer

A gene expression microarray data (GSE19422) was downloaded from Gene Expression Omnibus (GEO) database. The dataset contained 84 primary pheochromocytoma (PCC)/paraganglioma tumors and six normal adrenal gland tissues, and the platform of GPL6480-Agilent-014850 Whole Human Genome Microarray 4x44K G4112F (Probe Name version) was used for the analysis.¹¹ Gene symbols were annotated with the GPL6480 annotation file.

The mRNA expression of prognostic biomarkers involved in the lncRNA–miRNA–mRNA axis was plotted

Table 1 Top 25 Downregulated and Top 25 Upregulated mRNA

Top 25 Downregulated mRNA				Top 25 Upregulated mRNA			
Symbol	logFC	p-Value	FDR	Symbol	logFC	p-Value	FDR
SLC37A2	−4.7892	4.39E-23	4.68E-20	SLC8A3	6.647444	3.75E-10	1.11E-08
BAMBI	−4.52141	2.73E-18	8.15E-16	DCX	7.528979	1.78E-08	3.56E-07
KIAA1024	−4.52581	1.65E-17	3.86E-15	MCHR1	8.29453	1.66E-05	0.000144
FDX1	−4.71937	1.18E-16	2.00E-14	SYT2	6.630999	4.17E-05	0.000321
GALM	−4.45526	3.68E-16	5.50E-14	SOX11	10.68805	5.00E-05	0.000374
SLC16A9	−4.55815	1.06E-14	1.09E-12	POPDC3	6.767155	5.80E-05	0.000425
FDXR	−4.47427	1.51E-14	1.52E-12	OPRK1	8.275423	5.98E-05	0.000437
RGN	−4.45929	1.69E-14	1.65E-12	LINC00890	8.426037	8.39E-05	0.000579
ACSF2	−4.46773	2.39E-13	1.66E-11	FRMPD3	7.092507	0.000124	0.000811
ABCC3	−4.94181	4.25E-13	2.79E-11	WNT10A	8.291287	0.000184	0.001157
RBM47	−4.59347	7.39E-13	4.45E-11	SIX3	9.535783	0.000206	0.001268
APOC1	−4.89113	5.00E-12	2.33E-10	VWA5B1	7.094693	0.000255	0.001531
SEMA3B	−4.48062	1.31E-11	5.55E-10	RASSF6	8.27211	0.000575	0.003061
AVPR1A	−4.62031	1.90E-11	7.60E-10	APCDD1L	8.018701	0.000806	0.004064
AOX1	−5.13871	2.26E-11	8.86E-10	NAT16	6.691399	0.000983	0.004763
DHCR24	−4.70229	4.93E-11	1.77E-09	THSD7B	6.903341	0.001365	0.006258
TPD52L1	−4.68078	6.29E-11	2.20E-09	TMEM132D	7.417302	0.001967	0.008508
ALDH1L1	−4.53166	5.87E-10	1.67E-08	SHOX2	7.456944	0.002452	0.010212
NOV	−4.81279	6.29E-10	1.78E-08	NPY	7.471494	0.003273	0.012944
SLC47A1	−4.43845	6.60E-09	1.46E-07	KCNJ6	6.641958	0.003813	0.014677
NGEF	−4.64199	9.61E-09	2.04E-07	OPRM1	6.85908	0.007868	0.026291
ADGRV1	−4.61943	2.23E-08	4.35E-07	PCDH11X	7.112357	0.009235	0.029883
STAR	−5.34045	2.86E-08	5.42E-07	GNG8	7.149684	0.009424	0.03038
SERPINA5	−4.4036	3.61E-07	5.13E-06	ADCYAP1	7.827243	0.011811	0.036424
CYP11A1	−4.90555	1.03E-06	1.28E-05	CNTNAP4	6.819379	0.016655	0.047662

using TCGA-PCPG database and GSE19422 dataset. Overall survival and disease-free survival of these prognostic biomarkers in Pan-Cancer (excluding PCPG) were analyzed using the Gene Expression Profiling Interactive Analysis (GEPIA) database (<http://gepia.cancer-pku.cn/>).¹²

Immunohistochemistry (IHC)

Fifteen pairs of PCPG and adjacent adrenal gland tissues were collected from the Department of Urology, Second Xiangya Hospital of Central South University. At least two pathologists evaluated the HE staining of PCPG and adjacent adrenal gland tissues. Written informed consent was obtained from all patients and this study was approved by the Clinical Research Ethics Committee of the Second Xiangya Hospital of Central South University.

Patient samples harvested by surgical operation were fixed in neutral formalin and embedded in paraffin. Tissue slides were prepared and dewaxed by baking in an oven. The antigen retrieval was then carried out in a microwave oven with sodium citrate buffer pH 6.0 for 15 minutes,

then the endogenous peroxidase was blocked by incubation in 3% hydrogen peroxide for 25 minutes, and then 3% BSA was used to block for 30 minutes at room temperature. Then, the sample was incubated with rabbit anti-human RCAN3 polyclonal antibody (1:200; Bioss, Beijing, China, #bs-11542R) or rabbit anti-human PTPRJ polyclonal antibody (1:200; Proteintech, Wuhan, China, #55123-1-ap) at 4°C overnight, followed by incubation with the secondary antibody, goat anti-rabbit antibody (1:200; Servicebio, Wuhan, China, #G23301), at room temperature for 50 minutes. Substrate and hematoxylin staining were used, and the slides were imaged by a microscope. The region of interest in the adjacent adrenal gland was the medulla. The IHC profiler was used to evaluate IHC score by ImageJ. The calculated scores were defined as: high positive = score 4, positive = score 3, low positive = score 2, and negative = score 1. Statistical analysis was performed using the paired *t*-test. The two groups were taken to have significant differences when $p < 0.05$.

Table 2 Top 25 Downregulated and Top 25 Upregulated lncRNA

Top 25 Downregulated lncRNA				Top 25 Upregulated lncRNA			
Symbol	logFC	p-Value	FDR	Symbol	logFC	p-Value	FDR
AC073957.3	-3.76797	3.86E-17	8.01E-15	AC068700.1	5.634188	1.28E-11	5.45E-10
OIP5-AS1	-1.56095	5.60E-13	3.50E-11	AL022313.4	5.727269	1.34E-11	5.64E-10
ZNF503-AS2	-3.251	2.16E-11	8.57E-10	AL731557.1	5.794468	4.70E-10	1.37E-08
GSEC	-2.11874	2.36E-09	5.80E-08	AL390294.1	6.21209	5.81E-10	1.66E-08
DLGAP1-AS1	-2.68487	1.07E-08	2.25E-07	AL136964.1	5.748429	2.67E-09	6.49E-08
AC093157.1	-1.71001	6.11E-08	1.06E-06	AP002840.1	6.246437	6.31E-09	1.40E-07
AC026801.3	-2.28817	9.70E-08	1.60E-06	AL133163.3	6.110686	1.00E-08	2.12E-07
AL021453.1	-2.33787	1.08E-07	1.75E-06	AC105389.3	6.985011	2.29E-08	4.46E-07
AL354892.2	-1.72175	3.02E-07	4.36E-06	AC026369.1	5.772437	2.68E-08	5.11E-07
AC105942.1	-1.90242	7.62E-07	9.82E-06	MAPT-AS1	7.141991	1.39E-07	2.20E-06
AL445524.1	-1.891	1.44E-06	1.72E-05	AP006333.2	7.895482	1.75E-07	2.68E-06
LINC00174	-1.54625	5.17E-06	5.27E-05	LINC01930	5.840071	4.20E-07	5.85E-06
DANCR	-1.64292	5.70E-06	5.73E-05	LINC02287	5.736795	8.24E-07	1.05E-05
AC068888.1	-1.69542	1.11E-05	0.000102	AC010478.1	5.881153	1.23E-06	1.50E-05
NR2F1-AS1	-2.24175	1.84E-05	0.000157	AC005828.4	6.087545	4.65E-06	4.79E-05
MIR99AHG	-2.2713	2.05E-05	0.000173	LINC01982	6.1136	1.04E-05	9.67E-05
TMEM9B-AS1	-1.60771	5.64E-05	0.000415	UNC5B-AS1	5.868469	1.83E-05	0.000156
MIR22HG	-1.56325	0.000359	0.002056	KRTAP5-AS1	5.581534	2.19E-05	0.000184
ACVR2B-AS1	-1.53248	0.000457	0.002526	SATB1-AS1	5.683773	0.000118	0.000785
AC087741.1	-1.88727	0.000474	0.002606	GACAT2	5.635535	0.000123	0.000808
RNF144A-AS1	-2.29893	0.000715	0.003684	AC022893.2	5.704634	0.000135	0.000878
SH3BP5-AS1	-1.66577	0.000856	0.004266	AC079160.1	6.192744	0.000576	0.003066
CASC15	-1.81374	0.005303	0.019168	PPI4571	5.763316	0.003315	0.013082
HOTAIRM1	-1.59477	0.007733	0.025956	AC010931.2	6.202024	0.005343	0.019286
AL365181.3	-1.96367	0.009386	0.03028	LINC00648	5.741248	0.008911	0.029069

Table 3 Top 25 Downregulated and Top 25 Upregulated miRNA

Top 25 Downregulated miRNA				Top 25 Upregulated miRNA			
miRNA	logFC	p-Value	FDR	miRNA	logFC	p-Value	FDR
hsa-miR-193b-3p	-4.57576	3.27E-16	1.57E-13	hsa-miR-153-3p	4.037745206	8.05E-12	7.73E-10
hsa-miR-365a-3p	-3.5141	1.05E-15	1.68E-13	hsa-miR-153-5p	3.876958022	7.52E-07	2.93E-05
hsa-miR-365b-3p	-3.51402	1.05E-15	1.68E-13	hsa-miR-137	3.474046104	4.75E-06	0.000134212
hsa-miR-99a-5p	-2.77945	7.26E-12	7.73E-10	hsa-miR-7-5p	4.09855618	2.12E-05	0.000484566
hsa-let-7c-5p	-2.5734	3.80E-09	3.04E-07	hsa-miR-1179	3.927385921	0.000108253	0.001791778
hsa-miR-195-3p	-2.45674	8.70E-08	5.22E-06	hsa-miR-375	4.391892691	0.00015088	0.002263197
hsa-miR-195-5p	-2.36364	1.68E-07	8.95E-06	hsa-miR-483-5p	4.509825699	0.00029032	0.003275823
hsa-miR-497-5p	-2.26742	4.95E-07	2.16E-05	hsa-miR-2682-5p	4.747525655	0.000257548	0.003275823
hsa-miR-455-3p	-2.6539	1.11E-06	3.79E-05	hsa-miR-4705	6.267096508	0.000315449	0.003424384
hsa-miR-511-5p	-2.68334	3.73E-06	0.000112	hsa-miR-618	6.118619944	0.000366715	0.003667154
hsa-miR-424-5p	-2.05804	3.51E-05	0.000732	hsa-miR-129-1-3p	5.291642562	0.000388202	0.003802792
hsa-miR-199a-5p	-2.12296	4.31E-05	0.000863	hsa-miR-592	5.405166969	0.000603911	0.005085565
hsa-miR-450b-5p	-2.36939	6.82E-05	0.00126	hsa-miR-138-5p	4.551885502	0.000660335	0.005282681
hsa-miR-148a-5p	-2.58608	0.000136	0.002172	hsa-miR-483-3p	5.369779777	0.000971812	0.006760433
hsa-miR-100-5p	-2.07348	0.000239	0.003193	hsa-miR-410-5p	4.258720479	0.001106315	0.007479313
hsa-let-7c-3p	-2.05432	0.000261	0.003276	hsa-miR-873-5p	6.897992073	0.001176467	0.007631138
hsa-miR-508-3p	-3.51777	0.000358	0.00366	hsa-miR-138-1-3p	6.836301551	0.001554963	0.009693277
hsa-miR-214-5p	-1.88088	0.000516	0.00459	hsa-miR-196a-5p	4.2097511	0.002754991	0.015199949
hsa-miR-455-5p	-2.1107	0.001176	0.007631	hsa-miR-129-2-3p	5.147195976	0.003380698	0.018232979
hsa-miR-887-3p	-2.03233	0.00149	0.009412	hsa-miR-2682-3p	3.882001702	0.003507626	0.018707336
hsa-miR-450a-5p	-2.05002	0.001727	0.010142	hsa-miR-129-5p	4.292125863	0.00360147	0.018996767
hsa-miR-514a-3p	-3.20846	0.002123	0.012133	hsa-miR-3130-3p	4.001109161	0.00456375	0.022993542
hsa-miR-509-3p	-3.00819	0.005283	0.025782	hsa-miR-433-3p	3.795466062	0.006029191	0.028372661
hsa-miR-542-3p	-1.91368	0.005318	0.025782	hsa-miR-431-3p	3.497554636	0.007845611	0.034235393
hsa-miR-148a-3p	-1.86422	0.009125	0.038422	hsa-miR-541-3p	4.102786131	0.008572515	0.037070335

Results

Identification of Differentially Expressed lncRNA, miRNA, and mRNA

For a better understanding of the procedure used in this study, the workflow is presented in [Figure 1](#). Altogether, 178 PCPG samples and three normal adrenal gland samples were

included in the study. In total, 3496 mRNAs, 334 lncRNAs, and 116 miRNAs were obtained and met the inclusion criteria by comparing PCPG with normal adrenal gland tissue. The volcano plots and heatmaps are shown in [Figure 2](#). The top 25 upregulated and top 25 downregulated mRNAs are shown in [Table 1](#). Differentially expressed lncRNAs and differentially expressed miRNAs are shown in [Tables 2, 3](#) and , respectively.

Table 4 Prognostic Biomarkers in Pheochromocytoma and Paraganglioma

Types of RNA	Gene Symbols
lncRNA	AP006333.2, AP001486.2, AL133163.3, AL035071.1, AC156455.1, AC008969.1
mRNA	VPS37B, TTC38, RCAN3, PTPRJ, ORAI2, NTNG1, NKX3-1, MED12, MCM10, KIAA1958, IREB2, EPHA2, ENOSF1, CCNO, ANKRD36, ACAA1
miRNA	hsa-miR-148b-3p, hsa-miR-137, hsa-let-7b-3p, hsa-miR-338-5p, hsa-miR-338-3p, hsa-miR-181c-5p, hsa-miR-296-5p, hsa-miR-130b-3p

GO and KEGG Pathways Involved in PCPG

To investigate the function of differentially expressed mRNAs, analysis of the GO and KEGG pathways was performed. The main enriched biological processes were “synapse organization” ([Figure 3A](#)). The main enriched cellular components were “cell body” ([Figure 3B](#)). The main enriched molecular functions were “tubulin binding” ([Figure 3C](#)) ([Supplementary Table 1](#)). Differentially expressed genes were enriched in 59 KEGG signaling pathways ([Supplementary Table 2](#)) and the top 10 KEGG pathways are displayed in [Figure 3D](#). Although the major

Figure 3 GO and KEGG pathways enriched in tumor tissues. **(A)** The top 10 enriched biological processes of differentially expressed genes. **(B)** The top 10 enriched cellular components of differentially expressed genes. **(C)** The top 10 enriched molecular functions of differentially expressed genes. **(D)** Bubble plot showing the top 10 enriched pathways.

functions of these differentially expressed mRNAs in PCPG are related to the metabolism and hormone secretion signaling pathways, there were some metastasis-associated pathways, such as “ECM-receptor interaction”, “adherens junction”, and “cell adhesion molecules”; pathways associated with proliferation, such as “MAPK signaling pathway”; and cancer metabolism-associated pathways, such as “choline metabolism in cancer”, “central carbon metabolism in cancer”, and “AMPK signaling pathway”.

Identification of Prognostic Biomarkers

To identify the prognostic biomarkers in PCPG, Kaplan–Meier curves were plotted for each differentially expressed mRNA, miRNA, and lncRNA. In total, 16 mRNAs, six lncRNAs, and eight miRNAs were associated with the prognosis of PCPG patients (Table 4). For lncRNAs, the Kaplan–Meier curves of overall survival indicated that high expression of *AP006333.2*, *AP001486.2*, and *AL035071.1* was associated with good prognosis, whereas high expression of *AL133163.3*, *AC156455.1*, and *AC008969.1* was associated with poor prognosis (Figure 4). For miRNAs, the Kaplan–Meier curves of overall survival in this ceRNA network revealed that high expression of hsa-miR-148b-3p and hsa-miR-338-3p was associated with good prognosis (Figure 5). For mRNAs, the Kaplan–Meier curves of

overall survival showed that high expression of *VPS37B*, *TTC38*, *RCAN3*, *ORAI2*, *NTNG1*, *NKX3-1*, *EPHA2*, *ENOSF1*, and *ACAA1* was associated with good prognosis, whereas high expression of *PTPRJ*, *MED12*, *MCM10*, *KIAA1958*, *IREB2*, *CCNO*, and *ANKRD36* was associated with poor prognosis (Figure 6).

Different Expression of Prognostic Biomarkers Between Metastatic and Non-Metastatic PCPG Patients

By investigating the difference in expression of these prognostic biomarkers between metastatic patients and non-metastatic patients, we found that expression of hsa-miR-130b-3p and *IREB2* was significantly higher in metastatic patients than in non-metastatic patients. In contrast, *AP006333.2*, hsa-miR-137, *ACAA1*, and *NTNG1* were significantly more downregulated in metastatic patients compared with non-metastatic patients (Figure 7).

Regulatory ceRNA Network and Two lncRNA–miRNA–mRNA Axes in PCPG

By exploring the interaction between prognostic lncRNA and differentially expressed miRNA, and the interaction between differentially expressed miRNA and prognostic mRNA, we found 20 shared miRNAs. The ceRNA regulatory network was based on 16 mRNAs,

Figure 4 Kaplan-Meier survival curves for six differentially expressed long non-coding RNAs associated with overall survival in pheochromocytoma and paraganglioma. Six DElncRNAs are presented ($p < 0.05$): *AC008969.1*, *AC156455.1*, *AL035071.1*, *AL133163.3*, *AP001486.2*, and *AP006333.2*. The initial pathological diagnosis of patients was set as day 0. Horizontal axis represents overall survival time (days) and vertical axis represents survival probability.

Abbreviation: DElncRNAs, differentially expressed long non-coding RNAs.

Figure 5 Kaplan-Meier survival curves for two differentially expressed microRNAs associated with overall survival in pheochromocytoma and paraganglioma. Two DEmiRNAs are presented ($p < 0.05$): *hsa-miR-148b-3p* and *hsa-miR-338-3p*. The initial pathological diagnosis of patients was set as day 0. Horizontal axis represents overall survival time (days) and vertical axis represents survival probability.

Abbreviation: DEmiRNAs, differentially expressed microRNAs.

Figure 6 Kaplan-Meier survival curves for 16 differentially expressed mRNAs associated with overall survival in pheochromocytoma and paraganglioma. Sixteen DEmRNAs are presented ($p < 0.05$): *ACAA1*, *ANKRD36*, *CCNO*, *PTPRJ*, *ENOSF1*, *IREB2*, *KIAA1958*, *RCAN3*, *MCM10*, *MED12*, *NKX3-1*, *TTC38*, *NTNG1*, *ORAI2*, *VPS37B*, and *EPHA2*. The initial pathological diagnosis of patients was set as day 0. Horizontal axis represents overall survival time (days) and vertical axis represents survival probability.

Abbreviation: DEmRNAs, differentially expressed mRNAs.

six lncRNAs, and 20 shared miRNAs (Figure 8A). Based on the difference of expression and correlation between lncRNA and mRNA, two lncRNA-miRNA-

mRNA axes were identified: *AP001486.2/hsa-miR-195-5p/RCAN3* and *AP006333.2/hsa-miR-34a-5p/PTPRJ* (Figure 8B). There were statistically significant positive

Figure 7 Different expression of prognostic biomarkers between metastatic and non-metastatic PCPG patients. **(A)** Expression of lncRNA between metastatic and non-metastatic PCPG patients. **(B)** Expression of miRNA between metastatic and non-metastatic PCPG patients. **(C)** Expression of mRNA between metastatic and non-metastatic PCPG patients.

A

B

lncRNA/miRNA/mRNA			
axis	lncRNA	miRNA	mRNA
1	AP001486.2	hsa-miR-195-5p	RCAN3
2	AP006333.2	hsa-miR-34a-5p	PTPRJ

C

Figure 8 ceRNA network and regulatory axes. (A) A regulatory lncRNA-miRNA-mRNA ceRNA network in PCPG patients. Red: downregulated. Green: upregulated. Diamond shape: lncRNA. Rounded rectangle: miRNA. Triangle: mRNA. ceRNA: competitive endogenous RNA; PCPG: pheochromocytoma and paraganglioma. (B) Two lncRNA-miRNA-mRNA axes in the ceRNA network. (C) The expression of *AP001486.2* was positively correlated with *RCAN3* ($R=0.46$, $p=1.4 \times 10^{-10}$), whereas the expression of *AP006333.2* was positively correlated with *PTPRJ* ($R=0.53$, $p=2.2 \times 10^{-14}$). The expression of *hsa-miR-195-5p* was negatively correlated with *RCAN3* ($R=-0.19$, $p=0.01$) and *AP001486.2* ($R=-0.26$, $p=0.00057$), whereas the expression of *hsa-miR-34a-5p* was negatively correlated with *PTPRJ* ($R=-0.23$, $p=0.0023$) and *AP006333.2* ($R=-0.26$, $p=0.00057$).

A

B

Figure 9 Correlations between PCPG genotypes and lncRNA-miRNA-mRNA axes. **(A)** Correlation heatmap of susceptibility genes and lncRNA-miRNA-mRNA axes genes. **(B)** Correlation plot between *RET* and *AP006333.2*.

correlations between *AP001486.2* and *RCAN3* ($\text{cor}=0.46$, $p=1.4\text{e-}10$) and between *AP006333.2* and *PTPRJ* ($\text{cor}=0.53$, $p=2.2\text{e-}14$) (Figure 8C). There were significant negative correlations between *AP001486.2* and *hsa-miR-195-5p* ($\text{cor}=-0.26$, $p=0.00057$), *RCAN3* and *hsa-miR-195-5p* ($\text{cor}=-0.19$, $p=0.01$), *AP006333.2* and *hsa-miR-34a-5p* ($\text{cor}=-0.26$, $p=0.00057$), and *PTPRJ* and *hsa-miR-34a-5p* ($\text{cor}=-0.23$, $p=0.0023$).

Correlations Between PCPG Genotypes and lncRNA-miRNA-mRNA Axes

In order to investigate the correlations between susceptibility genes and lncRNA-miRNA-mRNA axes, we extracted the expression value of 20 susceptibility genes and the lncRNA-miRNA-mRNA axes. We found that *RET* highly correlated with *AP006333.2* in PCPG samples ($R=0.66$, $p<2.2\text{e-}16$) (Figure 9).

Figure 10 Enriched GO and KEGG pathways in the ceRNA network. (A) The top 5 enriched biological processes of the ceRNA network. (B) The top 5 enriched cellular components of the ceRNA network. (C) The top 5 enriched molecular functions of the ceRNA network. (D) Bubble plot showing the top 5 enriched pathways of the ceRNA network.

Enrichment Analysis Predicting the ceRNA Network

To predict the function of the ceRNA network, 16 mRNAs were involved in enrichment analysis of GO and KEGG pathways. The top 5 enriched biological processes (protein kinase B signaling, post-anal tail morphogenesis, positive regulation of cell junction assembly, negative regulation of protein kinase B signaling, and somitogenesis) are shown in Figure 10A. The top 5 enriched cellular components (ruffle membrane, specific granule, leading edge membrane, ruffle, and anchored

component of synaptic membrane) are shown in Figure 10B. The top 5 enriched molecular functions (hydro-lyase activity, carbon-oxygen lyase activity, beta-catenin binding, nuclear hormone receptor binding, and lyase activity) are shown in Figure 10C. The top 5 enriched KEGG pathways (axon guidance, alpha-linolenic acid metabolism, biosynthesis of unsaturated fatty acids, fructose and mannose metabolism, and fatty acid degradation) are shown in Figure 10D. These results show that mRNAs in the ceRNA network were enriched in metabolism-related pathways.

Figure 11 *PTPRJ* and *RCAN3* mRNA expression in TCGA and GSE19422 dataset. (A) *PTPRJ* and *RCAN3* mRNA expression levels in PCPG were compared to normal adrenal gland tissue samples based on TCGA-PCPG database. (B) *PTPRJ* and *RCAN3* mRNA expression levels in PCPG were compared to normal adrenal gland tissue levels based on the GSE19422 dataset.

Abbreviations: PCPG, pheochromocytoma and paraganglioma; TCGA, The Cancer Genome Atlas.

Figure 12 Immunohistochemistry (IHC) analysis of protein expression of RCAN3 and PTPRJ in adjacent adrenal gland and PCPG tissues. **(A)** IHC results of RCAN3 and PTPRJ protein expression in adjacent adrenal gland and PCPG tissues. **(B)** Histogram of protein expression of RCAN3 and PTPRJ indicating that they were both upregulated in PCPG tissue compared with adjacent adrenal gland tissues. Scale bar, 50 μ m.

Abbreviation: PCPG, pheochromocytoma and paraganglioma.

Validation of Expression Levels of *RCAN3* and *PTPRJ* and Prognostic Value in Pan-Cancer

Based on TCGA database, we found that *RCAN3* and *PTPRJ* expression levels in PCPG were higher than in normal adrenal gland tissue (*RCAN3*: $p=0.0021$; *PTPRJ*: $p=0.00031$). To validate the mRNA expression of *RCAN3*

and *PTPRJ*, we found a similar expression pattern of *RCAN3* and *PTPRJ* in pheochromocytoma/paraganglioma primary tumors based on the GSE19422 dataset (*RCAN3*: $p=0.00016$; *PTPRJ*: $p=0.014$) (Figure 11). The results of IHC further indicated higher protein expression levels of RCAN3 and PTPRJ in pheochromocytoma/paraganglioma primary tumors compared with adjacent adrenal gland

Figure 13 Overall survival and disease-free survival of *RCAN3* and *PTPRJ* mRNA expression in Pan-Cancer.

Abbreviations: TPM, transcripts per million; HR, hazard ratio; *RCAN3*, *RCAN* family member 3; *PTPRJ*, protein tyrosine phosphatase receptor type J.

medulla tissues (*RCAN3*: $p=0.0406$, *PTPRJ*: $p=0.0192$) (Figure 12). To further identify the prognostic value of *RCAN3* and *PTPRJ*, Kaplan–Meier curves of overall survival and disease-free survival in Pan-Cancer were plotted, and the high expression levels of *RCAN3* and *PTPRJ* were associated with a favorable prognosis (Figure 13).

Discussion

Previous studies have indicated that the mechanism of post-transcriptional regulation is complicated. Many factors, such as mRNA, miRNA, lncRNA, and circular RNA (circRNA), are involved. In our study, we integrally analyzed RNA-seq data and miRNA data of TCGA-PCPG and constructed a regulatory lncRNA–miRNA–mRNA network. Based on the ceRNA network, six lncRNAs, two miRNAs, and 16 mRNAs were identified as prognostic biomarkers in PCPG.

Several studies have identified differentially expressed genes of PCPG, which were different from those in our

study. One previous study compared malignant PCPG with the benign samples from TCGA and COMETE databases to investigate malignancy-induced differentially expressed genes. It found 11 signaling pathways that were related to metabolic alteration and cancer signaling.¹³ Among these signaling pathways, dopamine signaling and cAMP signaling were also reported in our study. Another study used 183 pheochromocytoma samples and three control samples to identify differentially expressed RNAs that were annotated by conversion through the Ensembl file (Homo sapiens GRCh38.87.chr.gtf). In that study, the threshold was adjusted by p -value <0.01 and $|\log_2 \text{fold change (FC)}| >2.0$.¹⁴ Circadian entrainment, cholinergic synapse, and aldosterone synthesis and secretion were considered as the paramount pathways in their study. In our study, we included 178 PCPG samples and three normal adrenal gland samples from TCGA database and used the threshold of $p < 0.05$ and $|\log_2(\text{fold change})| > 2$ to identify differentially expressed RNAs (lncRNA, miRNA, and

mRNA) which were annotated within Ensembl 90. These identified differentially expressed RNAs were enriched in some KEGG signaling pathways that were related to metabolism alteration, hormone changes produced by the adrenal gland and tumorigenesis biological behavior. Some KEGG signaling pathways overlapped with study by Liang et al,¹⁴ such as glutamatergic synapse, circadian entrainment, cholinergic synapse, and aldosterone synthesis and secretion. Furthermore, some metastasis-associated pathways (such as ECM–receptor interaction, adherens junction, and cell adhesion molecules), proliferation-associated pathway (such as the MAPK signaling pathway), and cancer metabolism-associated pathways (such as choline metabolism in cancer, central carbon metabolism in cancer, and the AMPK signaling pathway) were mentioned in our study.

Functional, pathogenesis-based classification deepens our understanding of PCPG. The mutation of susceptibility genes dysregulates biological functions in PCPG. Based on this functional classification of susceptibility genes, PCPG patients can be divided into two clusters (cluster 1 and cluster 2)¹⁵ and further divided into four major groups: the pseudohypoxia group (VHL, EGLN1, EPAS1, SDHx, SDHAF2, FH), the kinase signaling group (RET, HRAS, TMEM127, MAX), the Wnt signaling group (CSDE1, MAML3), and the disease-modifying gene group (ATRX, KMT2D, SETD2, TERT, TP53).¹⁰ In our study, we found SDHA, SDHB, and RET as differentially expressed genes and the GO analysis revealed that the tricarboxylic acid cycle enzyme complex is involved in cellular components. This suggested that most of the patients with PCPG in TCGA database were in the pseudohypoxia group, in accordance with the previous study's results.¹⁵

Studies on lncRNA in PCPG are emerging and several lncRNAs have been found to play a vital role in tumorigenesis and malignancy. Limited studies found that *SOX2OT*, *EFNA3*, and *MALAT-1* were involved in injury induced by dihydrogen peroxide,¹⁶ hypoxia,¹⁷ and chemical hypoxia in PC-12 cells,¹⁸ respectively. A previous study indicated that *LINC00472*, *RP11-455b3.1*, and *RP4-806M20.3* were associated with a poor clinical outcome in PCPG and the three lncRNAs served as prognostic biomarkers.¹⁹ More recently, another group identified *C9orf147* and *BSN-AS2* as independent prognostic lncRNAs for PCPG.¹⁴ In the present study, we identified that high expression of *AC008969.1*, *AC156455.1*, and *AL133163.3* predicted a good prognosis in PCPG, while high expression of *AP006333.2*, *AP001486.2*, and *AL035071.1* was associated with a poor prognosis. These six lncRNAs had not been reported in

previous studies and needed to be further studied for their function and underlying mechanisms in PCPG.

Many studies have reported that miRNAs act as prognostic biomarkers in PCPG, such as *miR-183*²⁰ and *miR-483-5p*.²¹ In our study, we found that high expression of two miRNAs, *hsa-miR-148b-3p* and *hsa-miR-338-3p*, was associated with a good prognosis in PCPG. Previous studies reported that *hsa-miR-338-3p* enhanced the risk of esophageal squamous cell carcinoma²² and decreased migration and invasion of colorectal carcinoma cells by targeting smoothened.²³ *miR-148b-3p* was also associated with the osteogenic differentiation capability of BM-MSCs.²⁴ These studies suggested various roles of *miR-338-3p* and *miR-148b-3p* in different diseases. In addition, we predicted that *hsa-miR-195-5p* and *hsa-miR-34a-5p* were involved in two lncRNA–miRNA–mRNA axes. *hsa-miR-195* was also involved in a ceRNA network constructed by Liang et al¹⁴ and *hsa-miR-195-5p* was an anti-oncogene to inhibit cell proliferation and angiogenesis.^{25,26} *hsa-miR-34a-5p* was reported to induce apoptosis and cell-cycle arrest, and suppressed tumor invasion and migration.²⁷

A number of mRNAs have been found as prognostic biomarkers in cancers.²⁸ In our study, mRNAs in the ceRNA network were enriched in metabolism-related signaling pathways. Two genes (*RCAN3*, *PTPRJ*) are important in two predicted lncRNA–miRNA–mRNA axes. *RCAN3* was a favorable prognostic biomarker while *PTPRJ* was an unfavorable marker in PCPG. *RCAN3* not only may be involved in immune response as an endogenous regulator of the calcineurin–nuclear factor of activated T cells (NFAT) signaling pathway,²⁹ but also plays a vital role in suppression of cancer.³⁰ *PTPRJ*, also named *CD148*, could negatively regulate T-cell activation and play a role in feedback inhibition of T-cell immune responses,³¹ which may result in a poor prognosis in PCPG. However, in malignant cancers, *PRPTJ* acted as a tumor suppressor to inhibit the proliferation of cancer,³² suggesting a potential different mechanism by which *PRPTJ* serves as a favorable biomarker in Pan-Cancer.

There are some limitations of this study. First, the ceRNA network produced by our inclusion and exclusion criteria was not static and the updated databases may lead to more interactions of lncRNA–miRNA and mRNA–miRNA and expand the ceRNA network. Second, more cohorts of PCPG are required to validate novel prognostic biomarkers.

In summary, we successfully constructed an lncRNA–miRNA–mRNA regulatory ceRNA network in PCPG and identified 16 mRNAs, six lncRNAs, and two miRNAs as prognostic biomarkers. *AP001486.2/hsa-miR-195-5p/*

RCAN3 and *AP006333.2/hsa-miR-34a-5p/PTPRJ* axes were predicted. These findings could contribute toward a better understanding of the biological mechanism of tumorigenesis of PCPG.

Abbreviations

ceRNA, competitive endogenous RNA; DElncRNA, differentially expressed lncRNA; DEMRNA, differentially expressed mRNA; DEMiRNA, differentially expressed miRNA; GO, gene ontology; KEGG, Kyoto Gene and Genomic Encyclopedia; PCPG, pheochromocytoma and paraganglioma; TCGA, The Cancer Genome Atlas.

Data Sharing Statement

The authors declare that the data supporting the findings of this study are available within the article.

Author Contributions

All authors have made great contributions to the concept and design, data acquisition or data analysis and interpretation; participated in the drafting of articles or strictly revised the content of important knowledge content; agreed to submit to the current journal; finally approved the version to be published; and agree to be responsible for all aspects of the work.

Funding

This study was supported by Hunan Provincial Natural Science Foundation of China (no. 2018JJ3762), the Fundamental Research Funds for the Central Universities of Central South University (no. 2018zzts262), China Scholarship Council (no. 201806370101, no. 201806375066), and the Scientific Research Project of Hunan Provincial Health Commission (no. 20190326). We would like to thank Editage for English language editing.

Disclosure

The authors declare that they have no conflict of interest.

References

- Pang Y, Liu Y, Pacak K, Yang C. Pheochromocytomas and paragangliomas: from genetic diversity to targeted therapies. *Cancers (Basel)*. 2019;11(4):436. doi:10.3390/cancers11040436
- Welander J, Andreasson A, Juhlin CC, et al. Rare germline mutations identified by targeted next-generation sequencing of susceptibility genes in pheochromocytoma and paraganglioma. *J Clin Endocrinol Metab*. 2014;99(7):E1352–60. doi:10.1210/jc.2013-4375
- Fishbein L, Leshchiner I, Walter V, et al. Comprehensive molecular characterization of pheochromocytoma and paraganglioma. *Cancer Cell*. 2017;31(2):181–193. doi:10.1016/j.ccell.2017.01.001
- Calsina B, Castro-Vega LJ, Torres-Perez R, et al. Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p/TSC2/mTOR axis in metastatic pheochromocytoma/paraganglioma. *Theranostics*. 2019;9(17):4946–4958. doi:10.7150/thno.35458
- Dhamija S, Diederichs S. From junk to master regulators of invasion: lncRNA functions in migration, EMT and metastasis. *Int J Cancer*. 2016;139(2):269–280. doi:10.1002/ijc.30039
- Job S, Georges A, Burnichon N, et al. Transcriptome analysis of lncRNAs in pheochromocytomas and paragangliomas. *J Clin Endocrinol Metab*. 2020;105(3):Mar. doi:10.1210/clinem/dgz168
- Ghosal S, Das S, Pang Y, et al. Long intergenic noncoding RNA profiles of pheochromocytoma and paraganglioma: a novel prognostic biomarker. *Int J Cancer*. 2020;146(8):2326–2335. doi:10.1002/ijc.32654
- Xiao X, Zhou T, Guo S, et al. lncRNA MALAT1 sponges miR-204 to promote osteoblast differentiation of human aortic valve interstitial cells through up-regulating Smad4. *Int J Cardiol*. 2017;243:404–412. doi:10.1016/j.ijcard.2017.05.037
- Li R, Qu H, Wang S, et al. GDCRNATools: an R/Bioconductor package for integrative analysis of lncRNA, miRNA and mRNA data in GDC. *Bioinformatics*. 2018;34(14):2515–2517. doi:10.1093/bioinformatics/bty124
- Kantorovich V, Pacak K. New insights on the pathogenesis of paraganglioma and pheochromocytoma. *F1000Res*. 2018;7:1500. doi:10.12688/f1000research.14568.1
- Lopez-Jimenez E, Gomez-Lopez G, Leandro-Garcia LJ, et al. Research resource: transcriptional profiling reveals different pseudo-hypoxic signatures in SDHB and VHL-related pheochromocytomas. *Mol Endocrinol*. 2010;24(12):2382–2391. doi:10.1210/me.2010-0256
- Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. *Nucleic Acids Res*. 2017;45(W1):W98–W102. doi:10.1093/nar/gkx247
- Suh YJ, Park JH, Bilegsaikhan SE, Lee DJ. Transcriptome analysis reveals significant differences in gene expression of malignant pheochromocytoma or paraganglioma. *Int J Endocrinol*. 2019;2019:7014240. doi:10.1155/2019/7014240
- Liang YC, Wu YP, Chen DN, et al. Building a competing endogenous RNA network to find potential long non-coding RNA biomarkers for pheochromocytoma. *Cell Physiol Biochem*. 2018;51(6):2916–2924. doi:10.1159/000496043
- Backman S, Maharjan R, Falk-Delgado A, et al. Global DNA methylation analysis identifies two discrete clusters of pheochromocytoma with distinct genomic and genetic alterations. *Sci Rep*. 2017;7:44943. doi:10.1038/srep44943
- Yin D, Zheng X, Zhuang J, Wang L, Liu B, Chang Y. Downregulation of long noncoding RNA Sox2ot protects PC-12 cells from hydrogen peroxide-induced injury in spinal cord injury via regulating the miR-211-myeloid cell leukemia-1 isoform2 axis. *J Cell Biochem*. 2018;119(12):9675–9684. doi:10.1002/jcb.27280
- Gong W, Qie S, Huang P, Xi J. Deletion of long noncoding RNA EFNA3 aggravates hypoxia-induced injury in PC-12 cells by upregulation of miR-101a. *J Cell Biochem*. 2019;120(1):836–847. doi:10.1002/jcb.27444
- Yang L, Xu F, Zhang M, et al. Role of lncRNA MALAT-1 in hypoxia-induced PC12 cell injury via regulating p38MAPK signaling pathway. *Neurosci Lett*. 2018;670:41–47. doi:10.1016/j.neulet.2018.01.036
- Ghosal S, Das S, Pang Y, et al. Long intergenic noncoding RNA profiles of pheochromocytoma and paraganglioma: a novel prognostic biomarker. *Int J Cancer*. 2019. doi:10.1002/ijc.32654
- Pillai S, Lo CY, Liew V, et al. MicroRNA 183 family profiles in pheochromocytomas are related to clinical parameters and SDHB expression. *Hum Pathol*. 2017;64:91–97. doi:10.1016/j.humpath.2017.03.017

21. Lowery AJ, Walsh S, McDermott EW, Prichard RS. Molecular and therapeutic advances in the diagnosis and management of malignant pheochromocytomas and paragangliomas. *The Oncologist*. 2013;18(4):391–407. doi:10.1634/theoncologist.2012-0410
22. Yang M, Liu R, Sheng J, et al. Differential expression profiles of microRNAs as potential biomarkers for the early diagnosis of esophageal squamous cell carcinoma. *Oncol Rep*. 2013;29(1):169–176. doi:10.3892/or.2012.2105
23. Xue Q, Sun K, Deng HJ, Lei ST, Dong JQ, Li GX. MicroRNA-338-3p inhibits colorectal carcinoma cell invasion and migration by targeting smoothed. *Jpn J Clin Oncol*. 2014;44(1):13–21. doi:10.1093/jjco/hyt181
24. Mollazadeh S, Fazly Bazzaz BS, Neshati V, et al. Overexpression of MicroRNA-148b-3p stimulates osteogenesis of human bone marrow-derived mesenchymal stem cells: the role of MicroRNA-148b-3p in osteogenesis. *BMC Med Genet*. 2019;20(1):117. doi:10.1186/s12881-019-0854-3
25. Cai C, He H, Duan X, et al. miR-195 inhibits cell proliferation and angiogenesis in human prostate cancer by downregulating PRR11 expression. *Oncol Rep*. 2018;39(4):1658–1670. doi:10.3892/or.2018.6240
26. Xu H, Hu YW, Zhao JY, et al. MicroRNA-195-5p acts as an anti-oncogene by targeting PHF19 in hepatocellular carcinoma. *Oncol Rep*. 2015;34(1):175–182. doi:10.3892/or.2015.3957
27. Haghi M, Taha MF, Javeri A. Suppressive effect of exogenous miR-16 and miR-34a on tumorigenesis of breast cancer cells. *J Cell Biochem*. 2019;120(8):13342–13353. doi:10.1002/jcb.28608
28. Chistiakov DA, Myasoedova VA, Grechko AV, Melnichenko AA, Orekhov AN. New biomarkers for diagnosis and prognosis of localized prostate cancer. *Semin Cancer Biol*. 2018;52(Pt 1):9–16. doi:10.1016/j.semcancer.2018.01.012
29. Park JS, Jeong JH, Byun JK, et al. Regulator of Calcineurin 3 ameliorates autoimmune arthritis by suppressing Th17 cell differentiation. *Am J Pathol*. 2017;187(9):2034–2045. doi:10.1016/j.ajpath.2017.05.008
30. Martinez-Hoyer S, Sole-Sanchez S, Aguado F, et al. A novel role for an RCAN3-derived peptide as a tumor suppressor in breast cancer. *Carcinogenesis*. 2015;36(7):792–799. doi:10.1093/carcin/bgv056
31. Harrod TR, Justement LB. Evaluating function of transmembrane protein tyrosine phosphatase CD148 in lymphocyte biology. *Immunol Res*. 2002;26(1–3):153–166. doi:10.1385/ir.26:1-3:153
32. Zhang XF, Tu R, Li K, Ye P, Cui X. Tumor Suppressor PTPRJ Is a Target of miR-155 in Colorectal Cancer. *J Cell Biochem*. 2017;118(10):3391–3400. doi:10.1002/jcb.25995

OncoTargets and Therapy

Dovepress

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic

agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/oncotargets-and-therapy-journal>